Key points are not available for this paper at this time.
Immune checkpoint inhibition represents a major recent breakthrough in the treatment of malignant diseases including breast cancer. Blocking the programmed death receptor-1 (PD-1) and its ligand, PD-L1, has shown impressive antitumor activity and may lead to durable long-term disease control, especially in the triple-negative subtypes of breast cancer (TNBC). Although immune checkpoint blockade is generally well tolerated, specific immune-related adverse events (irAEs) may occur. This review summarizes the clinical efficacy, perspectives, and future challenges of using PD-1/PD-L1-directed antibodies in the treatment of breast cancer.
Building similarity graph...
Analyzing shared references across papers
Loading...
Andreas D. Hartkopf
Florin‐Andrei Taran
Markus Wallwiener
Breast Care
Heidelberg University
University of Tübingen
Building similarity graph...
Analyzing shared references across papers
Loading...
Hartkopf et al. (Fri,) studied this question.
www.synapsesocial.com/papers/6916108be621bd59682e6e19 — DOI: https://doi.org/10.1159/000453569